文献速递神经免疫

MOG抗体相关疾病急性期血浆置换后的结局

Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
PubMed 文献 · Neurology · 2025-08-29

这项国际多中心回顾性队列研究纳入234例符合2023年MOGAD诊断标准、接受至少3次血浆置换(PLEX)且随访≥3个月的患者,评估PLEX后的完全恢复(CR)、临床显著改善(CSI)、视力和EDSS。结果显示视力和EDSS显著改善,在无后续发作的229次发作中44%达到CR、93%达到CSI;高龄和延迟启动PLEX与改善概率降低相关。

要点

  • MOGAD急性发作后接受PLEX,视力和EDSS均显著改善。
  • 无后续发作的发作中,44%完全恢复,93%临床显著改善。
  • 高龄和延迟启动PLEX与完全恢复及临床显著改善概率降低相关。

核心结论

  • MOGAD发作后接受PLEX可观察到良好结局,但高龄和延迟启动PLEX与改善概率降低相关。
  • 缺乏对照组限制区分PLEX效应与自发恢复、既往激素反应或长期免疫治疗。

研究设计与样本

  • 国际多中心回顾性队列研究,纳入6个国家18家三级中心的234例患者。
  • 纳入标准为符合2023年国际MOGAD专家组标准、接受至少3次PLEX、PLEX后随访≥3个月,并排除合并其他神经炎症性疾病者。
  • 共分析243次发作,中位年龄34岁(IQR 22-49),42例(17%)为儿童,135例(58%)为女性。

主要发现

  • 视神经炎视力从20/400(20/70-手动)改善至20/20(20/20-20/30),p < 0.001。
  • EDSS从中位数4.0(3.0-6.5)降至1.0(0.0-2.5),p < 0.001。
  • 在229次3个月内无后续发作的发作中,100次(44%)达到完全恢复,213次(93%)达到临床显著改善。
  • 完全恢复概率随年龄增长(调整OR 0.97 [95%CI 0.96-0.99] 每年)、EDSS较基线恶化程度更高(0.66 [0.54-0.81] 每0.5增量)和延迟PLEX(0.98 [0.96-0.99] 每天)而降低。
  • 临床显著改善概率随年龄增长(0.97 [95%CI 0.96-0.99] 每年)和延迟PLEX(0.95 [0.94-0.96] 每天)而降低。

关键数值与推荐

  • 165/243次(68%)发作中,接受PLEX治疗的发作为首次发作。
  • 发作表型包括161次视神经炎(235眼)、77次脊髓炎、24次急性播散性脑脊髓炎、15次脑干/小脑、3次大脑皮层脑炎、1次大脑多灶性缺损,36次有>1个核心表型。
  • 239次(99%)发作同时接受糖皮质激素治疗,32次(13%)接受IV免疫球蛋白治疗。

临床怎么用

  • 对于符合2023年国际MOGAD专家组标准的急性发作,PLEX可作为治疗选择之一。
  • 高龄和延迟启动PLEX与改善概率降低相关,提示应尽早考虑PLEX。

局限性

  • 缺乏对照组,无法区分PLEX效应与自发恢复、既往糖皮质激素反应或长期免疫治疗的影响。
  • 需要前瞻性研究评估PLEX对改善的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Data on the plasma exchange (PLEX) in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are limited. Herein, we evaluate outcomes after PLEX in MOGAD. METHODS: This international multicenter retrospective cohort study included patients from 18 tertiary care centers in 6 countries. Inclusion criteria included fulfillment of the 2023 International MOGAD panel criteria, receipt of at least 3 sessions of PLEX, and follow-up of ≥3 months after PLEX. Patients with coexisting neuroinflammatory disorders were excluded. We assessed the frequency of complete recovery (CR), clinically significant improvement (CSI), visual acuity (VA), and Expanded Disability Status Scale (EDSS). Logistic regression analyses were performed to identify predictors of CR and CSI. RESULTS: Of 234 patients, 135 (58%) were female. The median (interquartile range [IQR]) age at attack was 34 (IQR 22-49) years, and 42 (17%) were children. In 165 of 243 (68%), the attack treated with PLEX was the first attack. Attack phenotypes included 161 optic neuritis (235 eyes), 77 myelitis, 24 acute disseminated encephalomyelitis, 15 brainstem/cerebellar, 3 cerebral-cortical encephalitis attack, and 1 cerebral polyfocal deficit-36 with >1 core phenotypes. A total of 239 (99%) attacks were also treated with corticosteroids and 32 (13%) with IV immunoglobulins. VA in optic neuritis improved from 20/400 (20/70-hand motion) to 20/20 (20/20-20/30), p < 0.001, and EDSS decreased from a median of 4.0 (3.0-6.5) to 1.0 (0.0-2.5), p < 0.001. Of 229 attacks without subsequent attacks within 3 months, 100 (44%) achieved CR and 213 (93%) CSI. The probability of CR was decreased with advanced age (adjusted odd ratio [95% CI] 0.97 [0.96-0.99] per year), higher EDSS worsening from baseline (0.66 [0.54-0.81] per 0.5 increment) and delayed PLEX (0.98 [0.96-0.99] per day). Advanced age (0.97 [0.96-0.99] per year) and delayed PLEX (0.95 [0.94-0.96] per day) decreased the probability of CSI. DISCUSSION: We observed favorable outcomes after PLEX in MOGAD attacks. However, advanced age and delayed initiation of PLEX were associated with a reduced probability of improvement. The absence of a control group limits our ability to differentiate PLEX effects from spontaneous recovery, prior corticosteroid response, or long-term immunotherapy. Future prospective studies are needed to assess the impact of PLEX on improvement. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that PLEX is associated with favorable clinical outcomes in patients with MOGAD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Thakolwiboon S, Redenbaugh V, Chen B, et al. Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurology. 2025. PMID: 40882166. doi:10.1212/WNL.0000000000213903

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。